What are the latest funding news in the biotechnology market? (July 2026)
Download our beautiful pitch about the biotechnology market
In our biotechnology market deck, you will find everything you need to understand the market
Biotechnology funding stayed very active in late June and early July 2026, with large rounds still flowing into clinical therapeutics, biologics and genetic medicines.
The latest disclosed rounds show investors backing companies with clear clinical milestones, especially Phase 3 trials, IND preparation and first-in-human studies.
The biotechnology market is still broad, but the most recent funding news is concentrated in biopharma R&D, advanced delivery platforms and life-science research tools.
And if you want to better understand this new industry, you can download our pitch covering the biotechnology market.
Insights
- The 12 latest biotechnology funding deals represented about $1.52B, showing that private biotech investors were still willing to finance high-conviction clinical programs in July 2026
- Four rounds were above $200M, and each one was tied to serious late-stage or platform ambition, not early discovery alone
- Autoimmune and inflammatory disease startups were especially visible, with Beeline, Lycia and Oblenio together raising more than $563M
- Ophthalmology remained a strong biotechnology funding theme, with Healome and Ollin targeting very different parts of the eye-care value chain
- Genetic medicines stayed central to the biotechnology market, with Cyllene, ARTAN Bio and Serapha Bio all focused on gene delivery, editing or mutation correction
- The funding mix was unusually wide, from a $1M seed round for ARTAN Bio to a $426.3M upsized Series A for Beeline Medicines
- Many rounds were not just about discovery; investors funded specific next steps such as Phase 1 starts, Phase 3 launches, IND work and manufacturing scale-up
- Most companies had global clinical ambitions, but the market remained anchored in US, UK and European biotech hubs
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
Summary table of the latest funding deals in the biotechnology market as of July 2026
We define the biotechnology market as products and services that apply modern biological science and engineering to create or improve medical and life-science outcomes.
We include biopharma R&D and therapeutics, including biologics, cell/gene therapies, and vaccines, molecular diagnostics, and core life-science research tools and reagents used to generate and analyze biological data.
We exclude routine healthcare delivery, conventional pharmaceuticals and chemicals not enabled by biotechnology, and agriculture/industrial bioapplications unless they are explicitly in scope for the analysis.
You can also read our detailed analysis to understand how funding activity in the biotechnology market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the biotechnology market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Cyllene Therapeutics | 7 July 2026 | $37.7M | Series C | Gene Therapy & Genetic Medicines |
| Healome Therapeutics | 7 July 2026 | $2.6M | Seed | Ocular Drug Delivery & Biologics Delivery |
| Celea Therapeutics | 2 July 2026 | $180M | Debut financing | Respiratory Therapeutics & Biopharma R&D |
| ARTAN Bio | 1 July 2026 | $1M | Seed | Genetic Medicines & Molecular Therapeutics |
| Beeline Medicines | 30 June 2026 | $426.3M | Upsized Series A | Autoimmune Therapeutics & Biopharma R&D |
| Xellar Biosystems | 30 June 2026 | $50M | Series A and A+ | Life-Science Research Tools & 3D Biology Platforms |
| Lycia Therapeutics | 25 June 2026 | $75M | Series D | Protein Degradation & Immune Disease Therapeutics |
| Oblenio Bio | 25 June 2026 | $62M | Series B | Autoimmune Biologics & T-Cell Engagers |
| Anodyne Nanotech | 24 June 2026 | $12.6M | Series A | Biologics Delivery & Metabolic Therapeutics |
| RQ Bio | 24 June 2026 | $115M | Series A | Antibody Therapeutics & Infectious Disease Biologics |
| Ollin Biosciences | 24 June 2026 | $330M | Series B | Ophthalmology Biologics & Late-Stage Therapeutics |
| Serapha Bio | 23 June 2026 | $230M | Series A plus concurrent financing | Gene Editing & Genetic Medicines |
All the latest funding deals during in the biotechnology market as of July 2026
Cyllene Therapeutics raised about $37.7M in Series C funding in July 2026
When was it?
The deal was announced on 7 July 2026.
Who are they?
Cyllene Therapeutics, formerly EG 427, develops non-replicating HSV-1 genetic medicines that deliver therapeutic DNA to targeted neurons.
Geographical focus?
Cyllene Therapeutics is France-based and is building a clinical pipeline for global neurological and neuro-urology markets.
Why do we include them in the biotechnology market?
Cyllene Therapeutics belongs in biotechnology because its core product is a gene-therapy platform for targeted genetic medicine delivery.
What is the company stage?
Cyllene Therapeutics is a late clinical-stage biotech moving toward later-stage development.
How much did they raise?
Cyllene Therapeutics raised €33M, equal to about $37.7M for this round.
What round is it?
The financing was a Series C round.
Why did they raise?
Cyllene Therapeutics raised the round to advance EG110A and expand the HERMES HSV-1 gene-delivery platform.
Healome Therapeutics raised about $2.6M in seed funding in July 2026
When was it?
The deal was announced on 7 July 2026.
Who are they?
Healome Therapeutics develops an eye-drop matrix designed to keep drugs and biologics on the ocular surface for longer.
Geographical focus?
Healome Therapeutics is a UK spin-out with an initial focus on ocular surface diseases.
Why do we include them in the biotechnology market?
Healome Therapeutics belongs in biotechnology because its platform supports therapeutic delivery for biologics and ocular medicines.
What is the company stage?
Healome Therapeutics is preclinical and is working toward first-in-human studies expected in 2027.
How much did they raise?
Healome Therapeutics raised £2M, equal to about $2.6M for this round.
What round is it?
The financing was an oversubscribed seed round.
Why did they raise?
Healome Therapeutics raised the round to fund preclinical development, manufacturing scale-up, regulatory work and progress toward human trials.
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Celea Therapeutics raised $180M in debut financing in July 2026
When was it?
The deal was announced on 2 July 2026.
Who are they?
Celea Therapeutics develops deupirfenidone, a next-generation antifibrotic medicine for idiopathic pulmonary fibrosis.
Geographical focus?
Celea Therapeutics is a US and UK-linked PureTech-founded company targeting IPF markets globally.
Why do we include them in the biotechnology market?
Celea Therapeutics belongs in biotechnology because it is developing a clinical-stage therapeutic for fibrotic lung disease.
What is the company stage?
Celea Therapeutics is Phase 3-ready and preparing to test deupirfenidone in a pivotal program.
How much did they raise?
Celea Therapeutics raised $180M for this round.
What round is it?
The financing was a debut financing for the independent company.
Why did they raise?
Celea Therapeutics raised the round to start the Phase 3 SURPASS-IPF trial in early Q3 2026.
ARTAN Bio raised $1M in seed funding in July 2026
When was it?
The deal was announced on 1 July 2026.
Who are they?
ARTAN Bio develops engineered suppressor tRNA systems designed to restore protein translation in diseases caused by nonsense mutations.
Geographical focus?
ARTAN Bio is based in St. Petersburg, Florida, with no narrow regional disease focus disclosed.
Why do we include them in the biotechnology market?
ARTAN Bio belongs in biotechnology because its platform uses molecular engineering to develop genetic medicines.
What is the company stage?
ARTAN Bio is preclinical and is moving toward first-in-human development.
How much did they raise?
ARTAN Bio raised $1M for this round.
What round is it?
The financing was a seed round.
Why did they raise?
ARTAN Bio raised the round to move its codon suppression platform toward IND-enabling work, manufacturing and regulatory preparation.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Beeline Medicines raised an upsized $426.3M Series A in June 2026
When was it?
The upsized Series A was announced on 30 June 2026.
Who are they?
Beeline Medicines develops precision therapies for autoimmune and inflammatory diseases, led by afimetoran for systemic lupus erythematosus.
Geographical focus?
Beeline Medicines is US-based and is building programs for global autoimmune and inflammatory disease markets.
Why do we include them in the biotechnology market?
Beeline Medicines belongs in biotechnology because it is a clinical-stage drug developer focused on immune disease therapeutics.
What is the company stage?
Beeline Medicines is clinical-stage, with afimetoran expected to move toward pivotal development.
How much did they raise?
Beeline Medicines announced a $426.3M total Series A, including a $126.3M extension.
What round is it?
The financing was an upsized Series A and Series A extension.
Why did they raise?
Beeline Medicines raised the round to advance afimetoran into pivotal lupus development and start clinical studies for multiple candidates.
Xellar Biosystems raised $50M in Series A and A+ funding in June 2026
When was it?
The deal was announced on 30 June 2026.
Who are they?
Xellar Biosystems builds 3D human biology systems, organ-on-chip workflows, multi-omics data and AI models for drug discovery.
Geographical focus?
Xellar Biosystems is Boston-based and serves drug discovery customers globally.
Why do we include them in the biotechnology market?
Xellar Biosystems belongs in biotechnology because its tools generate and analyze biological data for life-science research.
What is the company stage?
Xellar Biosystems is a growth-stage platform company scaling its technology stack and infrastructure.
How much did they raise?
Xellar Biosystems raised $50M for this round.
What round is it?
The financing was a Series A and A+ round.
Why did they raise?
Xellar Biosystems raised the round to expand its 3D Bio Intelligence platform across organ-on-chip, lab automation, imaging and multi-omics.
In our biotechnology market deck, we identify pain points entrepreneurs should prioritize
Lycia Therapeutics raised $75M in Series D funding in June 2026
When was it?
The deal was announced on 25 June 2026.
Who are they?
Lycia Therapeutics develops LYTAC protein degraders that remove extracellular disease-causing proteins.
Geographical focus?
Lycia Therapeutics is based in South San Francisco, with no narrow regional focus disclosed.
Why do we include them in the biotechnology market?
Lycia Therapeutics belongs in biotechnology because its platform creates protein degradation medicines for autoimmune, inflammatory and allergic diseases.
What is the company stage?
Lycia Therapeutics is clinical-stage and is advancing candidates toward early clinical proof of concept.
How much did they raise?
Lycia Therapeutics raised $75M for this round.
What round is it?
The financing was a Series D round.
Why did they raise?
Lycia Therapeutics raised the round to advance LCA-0061 and LCA-0321 toward early clinical proof of concept.
Oblenio Bio raised $62M in Series B funding in June 2026
When was it?
The deal was announced on 25 June 2026.
Who are they?
Oblenio Bio develops LBL-051, a trispecific T-cell engager designed to reset the immune system in severe autoimmune diseases.
Geographical focus?
Oblenio Bio is based in Cambridge, Massachusetts, and its lead candidate was licensed from China’s Leads Biolabs.
Why do we include them in the biotechnology market?
Oblenio Bio belongs in biotechnology because it develops biologic immune-cell engager therapeutics for autoimmune disease.
What is the company stage?
Oblenio Bio is at a preclinical-to-clinical transition stage and is preparing LBL-051 for clinical development.
How much did they raise?
Oblenio Bio raised $62M for this round.
What round is it?
The financing was a Series B round.
Why did they raise?
Oblenio Bio raised the round to move LBL-051 into clinical development for autoimmune diseases.
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Anodyne Nanotech raised $12.6M in Series A funding in June 2026
When was it?
The deal was announced on 24 June 2026.
Who are they?
Anodyne Nanotech develops transdermal biologic delivery technology, led by ANN-101, a once-weekly GLP-1 patch.
Geographical focus?
Anodyne Nanotech is Boston-based and is initially targeting the obesity treatment market.
Why do we include them in the biotechnology market?
Anodyne Nanotech belongs in biotechnology because its HeroPatch platform is designed to deliver biologic medicines through the skin.
What is the company stage?
Anodyne Nanotech is clinical-stage and is preparing a Phase 1 trial.
How much did they raise?
Anodyne Nanotech raised $12.6M for this round.
What round is it?
The financing was a Series A round.
Why did they raise?
Anodyne Nanotech raised the round to advance ANN-101 into Phase 1 clinical trials and expand the HeroPatch platform.
RQ Bio raised $115M in Series A funding in June 2026
When was it?
The deal was announced on 24 June 2026.
Who are they?
RQ Bio develops long-acting antibody therapeutics for full-season influenza prevention in high-risk and immunocompromised people.
Geographical focus?
RQ Bio is UK-based and is building a global influenza-prevention program.
Why do we include them in the biotechnology market?
RQ Bio belongs in biotechnology because it develops antibody-based biologics for infectious disease prevention.
What is the company stage?
RQ Bio is preclinical-to-IND stage and is taking its lead antibody toward clinical testing.
How much did they raise?
RQ Bio raised $115M for this round.
What round is it?
The financing was a Series A round.
Why did they raise?
RQ Bio raised the round to advance RQB01 toward clinical testing and build a respiratory viral disease antibody pipeline.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Ollin Biosciences raised $330M in Series B funding in June 2026
When was it?
The deal was announced on 24 June 2026.
Who are they?
Ollin Biosciences develops OLN324, a VEGF and Ang2 bispecific antibody for diabetic macular edema and wet AMD.
Geographical focus?
Ollin Biosciences is based in Austin, Texas, and is preparing global Phase 3 retina studies.
Why do we include them in the biotechnology market?
Ollin Biosciences belongs in biotechnology because it develops biologic medicines for ophthalmology indications.
What is the company stage?
Ollin Biosciences is late clinical-stage and is preparing global Phase 3 trials.
How much did they raise?
Ollin Biosciences raised $330M for this round.
What round is it?
The financing was a Series B round.
Why did they raise?
Ollin Biosciences raised the round to fund global Phase 3 trials of OLN324 in DME and wet AMD.
Serapha Bio raised $230M in funding commitments in June 2026
When was it?
The deal was announced on 23 June 2026.
Who are they?
Serapha Bio develops SERP-01, an in vivo base-editing therapy for alpha-1 antitrypsin deficiency.
Geographical focus?
Serapha Bio is a US-based launch, with technology licensed from China’s YolTech Therapeutics.
Why do we include them in the biotechnology market?
Serapha Bio belongs in biotechnology because its lead program is an in vivo gene-editing therapy.
What is the company stage?
Serapha Bio is a newly launched clinical-development company funded into Phase 2 work and Phase 3 preparation.
How much did they raise?
Serapha Bio announced $230M in funding commitments, including $138M Series A plus $92M expected with the merger closing.
What round is it?
The financing was a Series A plus concurrent financing tied to a reverse merger.
Why did they raise?
Serapha Bio raised the round to complete Phase 2 testing, start Phase 3 preparation and fund operations into the second half of 2029.
Related blog posts
- How strong is fundraising in the biotechnology market right now?
- The latest news in the biotechnology market
- What is the true size of the biotechnology market?
- How funding activity has changed in the biotechnology market
- What are the key fundraising trends in the biotechnology market?
- A full list of funding deals in the biotechnology market
- The startups that have raised the most funding in the biotechnology market
- The most highly valued startups in the biotechnology market
- The full range of business models in the biotechnology market
